Key facts
- It has raised $62.7M; the latest was Early Stage VC ($35.0M) in Jan 2026.
- Notable investors include Highlight Capital, Hankang Capital, BioTrack Capital, Elikon Venture, InnoPinnacle — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for SciBrunch Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for SciBrunch Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SciBrunch Therapeutics
Operator of a biotechnology company focused on iterative innovation of small-molecule anti-tumor drugs. The company explores clinically validated targets from a new perspective, proactively designs differentiated product performance, and creates a globally competitive product pipeline.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Website
- scibrunch.com/
- Ownership
- Privately Held (backing)
SciBrunch Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SciBrunch Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SciBrunch Therapeutics in its N-PORT filings yet. We sweep new filings monthly.